h fabp dy1678 Search Results


elisa kits  (R&D Systems)
99
R&D Systems elisa kits
Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/h+fabp+dy1678/10__1161_slash_circheartfailure__120__007198-72-28-36?v=R%26D+Systems
Average 99 stars, based on 1 article reviews
elisa kits - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
immunosorbent assay elisa kits  (R&D Systems)
95
R&D Systems immunosorbent assay elisa kits
Characteristics of the study cohort.
Immunosorbent Assay Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/h+fabp+dy1678/pmc09864369-174-1-15?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
immunosorbent assay elisa kits - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
dy1678  (R&D Systems)
94
R&D Systems dy1678
Characteristics of the study cohort.
Dy1678, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/h+fabp+dy1678/pmc06678676-70-49-52?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
dy1678 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
h fabp  (R&D Systems)
93
R&D Systems h fabp
Characteristics of the study cohort.
H Fabp, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/h+fabp+dy1678/pm38136744-56-0-9?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
h fabp - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

Image Search Results


Characteristics of the study cohort.

Journal: Journal of Cardiovascular Development and Disease

Article Title: A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis—The Rise of IGF-BP2 and GDF-15

doi: 10.3390/jcdd10010022

Figure Lengend Snippet: Characteristics of the study cohort.

Article Snippet: Enzyme-linked immunosorbent assay (ELISA) kits (sST2: DY523, GDF-15: DY957, H-FABP: DY1678, IGF-BP2: DY674, suPAR: DY807, R&D Systems, Minneapolis, MN, USA) were used to quantify plasma levels of GDF-15, H-FABP, IGF-BP2, and suPAR.

Techniques:

Serum concentrations of sST2, GDF-15, H-FABP, IGF-BP2, suPAR, BNP, hsTN, and cTnI in patients with a PA/BSA value ≥ 16.6 mm/m 2 and with a PA/BSA value < 16.6 mm/m 2 ; ** p ≤ 0.010; * p ≤ 0.050. PA: pulmonary artery; BSA: body surface area; BNP: brain natriuretic peptide; cTnI: cardiac troponin I; hsTN: high-sensitive troponin; sST2: soluble suppression of tumorigenesis-2; GDF-15: growth/differentiation factor-15; H-FABP: heart-type fatty acid-binding protein; IGF-BP2: insulin-like growth factor binding protein 2; suPAR: soluble urokinase-type plasminogen activator receptor.

Journal: Journal of Cardiovascular Development and Disease

Article Title: A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis—The Rise of IGF-BP2 and GDF-15

doi: 10.3390/jcdd10010022

Figure Lengend Snippet: Serum concentrations of sST2, GDF-15, H-FABP, IGF-BP2, suPAR, BNP, hsTN, and cTnI in patients with a PA/BSA value ≥ 16.6 mm/m 2 and with a PA/BSA value < 16.6 mm/m 2 ; ** p ≤ 0.010; * p ≤ 0.050. PA: pulmonary artery; BSA: body surface area; BNP: brain natriuretic peptide; cTnI: cardiac troponin I; hsTN: high-sensitive troponin; sST2: soluble suppression of tumorigenesis-2; GDF-15: growth/differentiation factor-15; H-FABP: heart-type fatty acid-binding protein; IGF-BP2: insulin-like growth factor binding protein 2; suPAR: soluble urokinase-type plasminogen activator receptor.

Article Snippet: Enzyme-linked immunosorbent assay (ELISA) kits (sST2: DY523, GDF-15: DY957, H-FABP: DY1678, IGF-BP2: DY674, suPAR: DY807, R&D Systems, Minneapolis, MN, USA) were used to quantify plasma levels of GDF-15, H-FABP, IGF-BP2, and suPAR.

Techniques: Binding Assay

AUROC curves of sST2, GDF-15, H-FABP, IGF-BP2, suPAR, BNP, hsTN, and cTnI for prediction of a PA/BSA value ≥ 16.6 mm/m 2 with concerning cut-off values, Youden Indexes, sensitivity and specificity. BNP: brain natriuretic peptide; cTnI: cardiac troponin I; hsTN: high-sensitive troponin; sST2: soluble suppression of tumorigenesis-2; GDF-15: growth/differentiation factor-15; H-FABP: heart-type fatty acid-binding protein; IGF-BP2: insulin-like growth factor binding protein 2; suPAR: soluble urokinase-type plasminogen activator receptor.

Journal: Journal of Cardiovascular Development and Disease

Article Title: A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis—The Rise of IGF-BP2 and GDF-15

doi: 10.3390/jcdd10010022

Figure Lengend Snippet: AUROC curves of sST2, GDF-15, H-FABP, IGF-BP2, suPAR, BNP, hsTN, and cTnI for prediction of a PA/BSA value ≥ 16.6 mm/m 2 with concerning cut-off values, Youden Indexes, sensitivity and specificity. BNP: brain natriuretic peptide; cTnI: cardiac troponin I; hsTN: high-sensitive troponin; sST2: soluble suppression of tumorigenesis-2; GDF-15: growth/differentiation factor-15; H-FABP: heart-type fatty acid-binding protein; IGF-BP2: insulin-like growth factor binding protein 2; suPAR: soluble urokinase-type plasminogen activator receptor.

Article Snippet: Enzyme-linked immunosorbent assay (ELISA) kits (sST2: DY523, GDF-15: DY957, H-FABP: DY1678, IGF-BP2: DY674, suPAR: DY807, R&D Systems, Minneapolis, MN, USA) were used to quantify plasma levels of GDF-15, H-FABP, IGF-BP2, and suPAR.

Techniques: Binding Assay

Tabular overview of AUROC analyses of singular biomarkers for prediction of a PA/BSA value ≥ 16.6 mm/m 2 with concerning Youden Index, sensitivity, and specificity.

Journal: Journal of Cardiovascular Development and Disease

Article Title: A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis—The Rise of IGF-BP2 and GDF-15

doi: 10.3390/jcdd10010022

Figure Lengend Snippet: Tabular overview of AUROC analyses of singular biomarkers for prediction of a PA/BSA value ≥ 16.6 mm/m 2 with concerning Youden Index, sensitivity, and specificity.

Article Snippet: Enzyme-linked immunosorbent assay (ELISA) kits (sST2: DY523, GDF-15: DY957, H-FABP: DY1678, IGF-BP2: DY674, suPAR: DY807, R&D Systems, Minneapolis, MN, USA) were used to quantify plasma levels of GDF-15, H-FABP, IGF-BP2, and suPAR.

Techniques:

Tabular overview of AUROC analyses of a combination of 2 biomarkers for prediction of a PA/BSA value ≥ 16.6 mm/m 2 with concerning Youden Index, sensitivity, and specificity.

Journal: Journal of Cardiovascular Development and Disease

Article Title: A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis—The Rise of IGF-BP2 and GDF-15

doi: 10.3390/jcdd10010022

Figure Lengend Snippet: Tabular overview of AUROC analyses of a combination of 2 biomarkers for prediction of a PA/BSA value ≥ 16.6 mm/m 2 with concerning Youden Index, sensitivity, and specificity.

Article Snippet: Enzyme-linked immunosorbent assay (ELISA) kits (sST2: DY523, GDF-15: DY957, H-FABP: DY1678, IGF-BP2: DY674, suPAR: DY807, R&D Systems, Minneapolis, MN, USA) were used to quantify plasma levels of GDF-15, H-FABP, IGF-BP2, and suPAR.

Techniques:

Two-way biomarker combinations with corresponding AUROC analyses and diagnostic strength; # YI ≥ 35; ## YI ≥ 40. BNP: brain natriuretic peptide; cTnI: cardiac troponin I; hsTN: high-sensitive troponin; sST2: soluble suppression of tumorigenesis-2; GDF-15: growth/differentiation factor-15; H-FABP: heart-type fatty acid-binding protein; IGF-BP2: insulin-like growth factor binding protein 2; suPAR: soluble urokinase-type plasminogen activator receptor; YI: Youden Index.

Journal: Journal of Cardiovascular Development and Disease

Article Title: A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis—The Rise of IGF-BP2 and GDF-15

doi: 10.3390/jcdd10010022

Figure Lengend Snippet: Two-way biomarker combinations with corresponding AUROC analyses and diagnostic strength; # YI ≥ 35; ## YI ≥ 40. BNP: brain natriuretic peptide; cTnI: cardiac troponin I; hsTN: high-sensitive troponin; sST2: soluble suppression of tumorigenesis-2; GDF-15: growth/differentiation factor-15; H-FABP: heart-type fatty acid-binding protein; IGF-BP2: insulin-like growth factor binding protein 2; suPAR: soluble urokinase-type plasminogen activator receptor; YI: Youden Index.

Article Snippet: Enzyme-linked immunosorbent assay (ELISA) kits (sST2: DY523, GDF-15: DY957, H-FABP: DY1678, IGF-BP2: DY674, suPAR: DY807, R&D Systems, Minneapolis, MN, USA) were used to quantify plasma levels of GDF-15, H-FABP, IGF-BP2, and suPAR.

Techniques: Biomarker Assay, Diagnostic Assay, Binding Assay

Tabular overview of AUROC analyses of a combination of 3 biomarkers for prediction of a PA/BSA value ≥ 16.6 mm/m 2 with concerning Youden Index, sensitivity, and specificity.

Journal: Journal of Cardiovascular Development and Disease

Article Title: A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis—The Rise of IGF-BP2 and GDF-15

doi: 10.3390/jcdd10010022

Figure Lengend Snippet: Tabular overview of AUROC analyses of a combination of 3 biomarkers for prediction of a PA/BSA value ≥ 16.6 mm/m 2 with concerning Youden Index, sensitivity, and specificity.

Article Snippet: Enzyme-linked immunosorbent assay (ELISA) kits (sST2: DY523, GDF-15: DY957, H-FABP: DY1678, IGF-BP2: DY674, suPAR: DY807, R&D Systems, Minneapolis, MN, USA) were used to quantify plasma levels of GDF-15, H-FABP, IGF-BP2, and suPAR.

Techniques:

Three-way biomarker combinations with corresponding AUROC analyses and diagnostic strength; # YI ≥ 35; ## YI ≥ 40. BNP: brain natriuretic peptide; cTnI: cardiac troponin I; hsTN: high-sensitive troponin; sST2: soluble suppression of tumorigenesis-2; GDF-15: growth/differentiation factor-15; H-FABP: heart-type fatty acid-binding protein; IGF-BP2: insulin-like growth factor binding protein 2; suPAR: soluble urokinase-type plasminogen activator receptor; YI: Youden Index.

Journal: Journal of Cardiovascular Development and Disease

Article Title: A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis—The Rise of IGF-BP2 and GDF-15

doi: 10.3390/jcdd10010022

Figure Lengend Snippet: Three-way biomarker combinations with corresponding AUROC analyses and diagnostic strength; # YI ≥ 35; ## YI ≥ 40. BNP: brain natriuretic peptide; cTnI: cardiac troponin I; hsTN: high-sensitive troponin; sST2: soluble suppression of tumorigenesis-2; GDF-15: growth/differentiation factor-15; H-FABP: heart-type fatty acid-binding protein; IGF-BP2: insulin-like growth factor binding protein 2; suPAR: soluble urokinase-type plasminogen activator receptor; YI: Youden Index.

Article Snippet: Enzyme-linked immunosorbent assay (ELISA) kits (sST2: DY523, GDF-15: DY957, H-FABP: DY1678, IGF-BP2: DY674, suPAR: DY807, R&D Systems, Minneapolis, MN, USA) were used to quantify plasma levels of GDF-15, H-FABP, IGF-BP2, and suPAR.

Techniques: Biomarker Assay, Diagnostic Assay, Binding Assay